CD8A and central nervous system cancer: Intratumoral mitoxantrone administration in a murine CD24-high glioma model extended survival, decreased tumor size, reduced Siglec-10<sup>+</sup>/TREM2<sup>+</sup> cell populations, and increased anti-tumor CD8<sup>+</sup> cells.